US-based clinical development firm AltheRx Pharmaceuticals has received a notice of allowance for its patent application from the US Patent and Trademark Office (USPTO) for the use of solabegron in combination with antimuscarinics at both therapeutic and sub-therapeutic doses, for the treatment of overactive bladder (OAB).
The clinical data shows that the combination of solabegron and antimuscarinics has a synergistic effect on the bladder and also has the potential to improve treatment outcomes and satisfy the unmet needs of millions of patients suffering from OAB symptoms.
Vanderbilt University professor of Department of Urology Roger Dmochowski said clinical data shows that solabegron has the potential to become a highly effective and competitive mono-therapy.
"AltheRx's discovery of the synergy created by the combined use of solabegron with an antimuscarinic is significant because it holds the promise of a new standard of pharmaceutical treatment for overactive bladder," Dmochowski said.
The company is currently developing solabegron, a novel beta 3-adrenergic receptor agonist with high affinity and selectivity, for the treatment of OAB patients.
The Phase II clinical results showed a significant improvement with solabegron compared to placebo, with favorable tolerability.
According to the company, Solabegron is now ready to enter Phase III trials in the EU and the US.
AltheRx is also in discussions to progress the development of the drug through late stage clinical development and finally into global commercialization.